Results 251 to 260 of about 34,445,663 (284)
Some of the next articles are maybe not open access.
Glucagon-like peptide-1 receptor agonists
2016Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
openaire +1 more source
Glucagon-Like Peptide-1 Receptor Agonists and Youth Obesity
JAMA PediatricsThis Viewpoint discusses the use of glucagon-like peptide-1 receptor agonist treatments for weight management in youth.
Emma K, Edmondson +2 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists in Gynecologic Surgery
Obstetrics & GynecologyGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly expanded beyond their initial role in diabetes management to become prominent agents for weight loss and metabolic optimization. A growing number of patients receiving these therapies are presenting for gynecologic surgery. This narrative review summarizes current evidence on GLP-1 RAs,
Richard, Hsu +3 more
openaire +2 more sources
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
International Journal of COPD, 2023Jun Chen, Jishun Chen, Hang Qian
exaly
Glucagon-Like Peptide-1 Receptor Agonists and Cancer
JAMA OncologyMahyar, Etminan +2 more
openaire +4 more sources
Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?
JAMA Internal Medicine, 2022Shanzay, Haider, Kasia J, Lipska
openaire +2 more sources